FDA Approved: MYALEPT — Supplemental Application (Chiesi USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for MYALEPT (metreleptin) submitted by Chiesi USA, Inc. The action updates the product's labeling/approval details.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Generalized Lipodystrophy
• Generalized Lipodystrophy

Drugs mentioned

• MYALEPT (METRELEPTIN)

Snippet

SUPPL AP for MYALEPT (METRELEPTIN)